RNA therapies, immunotherapy and advanced diagnostics in the fight against antimicrobial resistance

Antimicrobial resistance (AMR) is considered one of the greatest threats to public health worldwide. The END-RAM project, led by Certest Biotec, is a consortium-based initiative aimed at developing new advanced therapies based on RNA and cell therapy, along with rapid and advanced diagnostic platforms that enable early detection of resistant bacteria and the selection of the most appropriate treatment.

This initiative brings together the clinical, technological, and biotechnological expertise of a multidisciplinary consortium of leading companies and research organizations. Its dual objective is to improve diagnostic and therapeutic responses against resistant infections, while also driving technologies applicable to other fields such as next-generation vaccines or personalized therapies.

Project MIG-20242017 funded by the CDTI and supported by the Ministry of Science, Innovation, and Universities.